Protalix BioTherapeutics Inc. (PLX) Sees Large Increase in Short Interest
Protalix BioTherapeutics Inc. (NYSE:PLX) was the target of a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 742,145 shares, an increase of 4.2% from the September 15th total of 712,565 shares. Based on an average daily trading volume, of 58,421 shares, the short-interest ratio is presently 12.7 days. Approximately 0.8% of the company’s stock are short sold.
A number of analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Protalix BioTherapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, September 7th. Jefferies Group dropped their price target on shares of Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating for the company in a research note on Tuesday, September 6th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Protalix BioTherapeutics in a research note on Monday, July 11th.
Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 0.4851 on Wednesday. The firm’s 50-day moving average is $0.59 and its 200 day moving average is $0.71. Protalix BioTherapeutics has a 1-year low of $0.49 and a 1-year high of $1.25. The company has a market cap of $48.39 million and a price-to-earnings ratio of 0.9587.
Protalix BioTherapeutics (NYSE:PLX) last released its quarterly earnings data on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. The company earned $1.77 million during the quarter, compared to analysts’ expectations of $1.34 million. During the same quarter in the prior year, the company earned ($0.05) EPS. Equities analysts expect that Protalix BioTherapeutics will post ($0.41) EPS for the current fiscal year.
Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.